Isotechnika Inc.

Isotechnika Enrols First Patient in Phase IIb Kidney Transplant Trial

    Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company enrolled its first  patient in a North American Phase IIb kidney transplant trial for its lead immunosuppressive drug, ISA247, on January 4, 2006.

    The trial will be performed at thirty-four centers across North America , including twenty-nine centers in the United States and five centers in  Canada. A total of 332 de novo (newly transplanted) kidney transplant  patients will be enrolled in this trial. Patients will be placed into one  of four separate treatment groups; three different dose groups of ISA247 (0 .4 mg/kg, 0.6 mg/kg, and 0.8 mg/kg twice daily) compared with the fourth  group, a tacrolimus (0.05 mg/kg twice daily) control arm. Patients in all  four treatment groups will have their doses adjusted in order to achieve pre-defined blood levels of either ISA247 or tacrolimus. All patients will  receive oral treatment of drug (ISA247 or tacrolimus) over a six month  period along with other standard immunosuppressive therapies used following  transplantation.

    The primary endpoint of the trial is defined as non-inferiority in biopsy proven acute rejection (BPAR) episodes in patients receiving ISA247  for six months as compared to the tacrolimus control. Additionally, kidney  function and other laboratory parameters such as hypertension,  hyperlipidemia and new onset diabetes mellitus will be monitored for the  duration of the trial. The overall goal of the trial is to find the most  appropriate dose that will result in efficacy (lack of rejection) with  minimal side effects that are typically seen with other calcineurin  inhibitors such as cyclosporine and tacrolimus.

    "Enrolling our first patient in a timely manner speaks to our ongoing  commitment to development timelines," stated Dr. Randall Yatscoff,  Isotechnika's President & CEO. "We are excited to move ISA247 forward in  the area of transplantation as well as for the treatment of psoriasis. We  look forward to providing future progress reports to the investment and  scientific communities in both of these areas."

    About Isotechnika

    Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in  medicinal chemistry and immunology, the Company is focused on the discovery  and development of novel immunosuppressive therapeutics that are safer than  currently available treatments. Its entrepreneurial management and world- class team of scientists are building a pipeline of immunosuppressive drug  candidates for treatment of autoimmune diseases and for use in the  prevention of organ rejection in transplantation. Isotechnika looks to  become the leader in development of immunosuppressant therapies.

    Isotechnika's lead compound, ISA247 is an immunosuppressant currently  in an extension protocol of a Canadian Phase III human clinical trial for  the treatment of moderate to severe psoriasis. In addition, ISA247 has  successfully completed a Phase IIa trial for kidney transplantation. The  Company also has an additional immunosuppressive compound in its drug  pipeline, TAFA93 which is in Phase I.

    Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol ISA. More information on Isotechnika can be found at


    Isotechnika Inc. has a collaboration agreement with Hoffman La Roche  which licensed the worldwide rights to develop and commercialize  Isotechnika's novel molecule ISA247 for all transplant indications.

    In addition, the Company has an exclusive worldwide licensing agreement  with Atrium Medical Corporation for the use of ISA247 and TAFA93  specifically with drug eluting devices for the non-systemic treatment of  vascular, cardiovascular, target vessel and tissue disorders.

    Forward-Looking Statements

    This press release may contain forward-looking statements. Forward looking statements, including the Company's belief as to the potential of  its products, the Company's expectations regarding the issuance of  additional patents and the Company's ability to protect its intellectual  property, involve known and unknown risks and uncertainties, which could  cause the Company's actual results to differ materially from those in the  forward looking statements. Such risks and uncertainties include, among  others, the availability of funds and resources to pursue research and  development projects, the ability to economically manufacture its products,  the potential of its products, the success and timely completion of  clinical studies and trials, the Company's ability to successfully  commercialize its products, the ability of the Company to defend its  patents from infringement by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of  others. Investors should consult the Company's quarterly and annual filings  with the Canadian commissions for additional information on risks and  uncertainties relating to the forward- looking statements. Investors are  cautioned against placing undue reliance on forward-looking statements.

ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar:

For further information: Dr. Randall Yatscoff, President & CEO,  
Isotechnika Inc., Phone: +1-(780)-487-1600 Ext. 246, Fax:
+1-(780)-484-4105, Email:; Stephanie
Gillis-Paulgaard, Director,  Corporate Communications, Isotechnika
Inc., Phone: +1-(780)-909-4661, Fax: +1-(780)-484-4105, E-mail:; To request a free copy of this
organization's annual report, please go to and
click on Tools for Investors.

Weitere Meldungen: Isotechnika Inc.

Das könnte Sie auch interessieren: